Study of JSKN016 for advanced HER2-negative breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination drug (JSKN016) for people with HER2-negative breast cancer that has spread or cannot be removed. It is for those who have not yet had advanced-stage treatment (except hormone therapy) and may offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-negative breast cancer that has spread and cannot be removed by surgery.
- If your cancer is hormone receptor-positive, you have already tried standard hormone therapy and it stopped working or you cannot take it.
- You have not had any systemic treatment (like chemotherapy or targeted therapy) for advanced disease, except for hormone therapy or CDK4/6 inhibitors.
- Your cancer has gotten worse after your last treatment, based on scans.
- You are generally in good health, able to do daily activities, and have adequate organ function (heart, liver, kidneys, bone marrow).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two study drugs (JSKN016 and D-0502) for people with a common type of advanced breast cancer (HR-positive, HER2-negative) that has grown after standard hormonal and CDK4/6 inhibitor treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
This trial compares a new targeted therapy (JSKN003) against Kadcyla (T-DM1) for people with HER2-positive breast cancer that has advanced or spread. Both drugs work by attaching a chemotherapy directly to HER2-positive cancer cells, and the study aims to see if the new drug works better or has fewer side effects.
This study tests an investigational drug called KJ015 for people with HER2-positive solid tumors (cancer that has a specific protein on its surface). The goal is to see if the drug is safe and effective in treating your type of cancer.
This trial compares a new experimental drug, JSKN003, to standard treatments chosen by your doctor for advanced breast cancer that tests as HER2-low (IHC 1+ or 2+ but not amplified). It's for people whose cancer has spread or can't be removed and who have already had one or two lines of chemotherapy.
This study tests a new drug called JSKN016 against standard chemotherapy options for triple-negative breast cancer that has stopped responding to previous treatments. The trial aims to find out if JSKN016 works better or offers other benefits for patients like you.
Hear when a new Inoperable Locally Advanced HER2-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.